{"id":"https://genegraph.clinicalgenome.org/r/fa3ba00b-093a-4469-adcd-59130ac55044v1.6","type":"EvidenceStrengthAssertion","dc:description":["SMARCA2 was first reported in relation to autosomal dominant intellectual disability-sparse hair-brachydactyly syndrome (also known as Nicolaides-Baraitser syndrome) in 2012\n(Van Houdt et al., PMID: 22366787). Numerous missense variants, all of which occur in highly conserved ATPase motifs, have been reported in humans. Evidence supporting the relationship between SMARCA2 and intellectual disability-sparse hair-brachydactyly syndrome includes case-level, and experimental data. Summary of case-level data: 11.5 points. De novo missense variants in SMARCA2 with proposed dominant negative mechanism (PMIDs: 8871545, 22366787) have been reported in at least 17 probands in 5 publications (PMIDs: 22366787, 25249037, 23906836, 25724810, 22822383). Of note: a handful of loss-of-function variants in SMARCA2 have been identified in large neurodevelopmental disorder cohorts (example PMID 31112269), however the clinical features were not described in depth. Since itâ€™s unclear if loss-of-function variants cause the full clinical spectrum, they were not included in this curation. Summary of experimental data: 1.5 pts. This gene-disease association is supported by in vitro functional assays and cell culture models. In summary, SMARCA2 is definitively associated with autosomal dominant intellectual disability-sparse hair-brachydactyly syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Intellectual Disability and Autism Working Group on 8/18/2020 (SOP Version 7). \n \nLumping and splitting considerations:\n \nSMARCA2 is associated with:\nOrphanet: Intellectual disability-sparse hair-brachydactyly syndrome\nOMIM: Nicolaides-Baraitser syndrome\n \nPer criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism, inheritance pattern, or phenotypic variability (which can include intellectual disability, sparse hair, prominent interphalangeal joints, coarse facies, microcephaly, and seizures). Therefore, all of the disease entities have been lumped into one disease entity, intellectual disability-sparse hair-brachydactyly syndrome.\n","*SMARCA2* was first reported in relation to autosomal dominant intellectual disability-sparse hair-brachydactyly syndrome, also known as Nicolaides-Baraitser syndrome, in 2012 (Van Houdt et al., PMID: 22366787). Numerous missense variants, all of which occur in highly conserved ATPase motifs, have been reported. Sixteen *de novo* missense variants that have been reported in 17 probands in 5 publications (PMIDs: 22366787, 22822383, 23906836, 25249037, 25724810) are included in this curation. The mechanism of pathogenicity is suggested to be dominant negative (PMIDs: 8871545, 22366787). Note that a few loss-of-function variants in *SMARCA2* have been identified in large neurodevelopmental disorder cohorts (e.g., PMID: 31112269), but the clinical features were not described in depth. Since it is unclear if loss-of-function variants cause the full clinical spectrum, they were not included in this curation. This gene-disease relationship is also supported by *in vitro* functional assays and cell culture models.\n\nIn summary, there is definitive evidence supporting the relationship between *SMARCA2* and autosomal dominant intellectual disability-sparse hair-brachydactyly syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel  on August 18, 2020 (SOP Version 7). "],"dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/fa3ba00b-093a-4469-adcd-59130ac55044","GCISnapshot":"https://genegraph.clinicalgenome.org/r/5cde86bc-f99f-40cf-8c32-eac9f8f8a67d","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/5cde86bc-f99f-40cf-8c32-eac9f8f8a67d_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2025-08-22T14:01:08.209Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/5cde86bc-f99f-40cf-8c32-eac9f8f8a67d_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":["2020-08-18T16:00:00.000Z","2020-08-18T10:00:00.000Z"],"role":"Approver"}],"curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5cde86bc-f99f-40cf-8c32-eac9f8f8a67d_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de76edb0-2868-4688-87f4-b69a90eecdba","type":"EvidenceLine","dc:description":"Awarding 1 pt because variant was identified by trio exome sequencing, phenotype is specific, and variant occurs in ATPase domain, a functionally important domain where other pathogenic missense variants cluster.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de76edb0-2868-4688-87f4-b69a90eecdba_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25724810","allele":{"id":"https://genegraph.clinicalgenome.org/r/dccde933-c650-48de-9346-5de309b7c2fc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.2642G>A (p.Gly881Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372785050"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ec5822b6-aa93-4ebe-81c7-c66074866966","type":"EvidenceLine","dc:description":"Awarding 1 pt because variant was identified by trio exome sequencing, phenotype is specific, and variant occurs in ATPase domain, a functionally important domain where other pathogenic missense variants cluster.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ec5822b6-aa93-4ebe-81c7-c66074866966_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25724810","allele":{"id":"https://genegraph.clinicalgenome.org/r/ba57b74c-6d46-45b2-beca-ec8fab4b9aba","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.3655G>C (p.Ala1219Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372789068"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/620e3949-1951-46eb-8d09-79adb5ee93e7","type":"EvidenceLine","dc:description":"GCEP suggested awarding 1 pt because variant was identified by exome sequencing, phenotype is specific, and variant occurs in ATPase domain, a functionally important domain where other pathogenic missense variants cluster.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/620e3949-1951-46eb-8d09-79adb5ee93e7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22366787","allele":{"id":"https://genegraph.clinicalgenome.org/r/f3f31d4c-b0d0-48d1-94a3-4ff126992add","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.3473A>T (p.Asp1158Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA211265"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/8fd81e99-e91f-459a-8ccd-89e73fc85941","type":"EvidenceLine","dc:description":"Awarding 0.5 pt because variant was identified by NGS sequencing panel, phenotype is specific, and variant occurs in ATPase domain, a functionally important domain where other pathogenic missense variants cluster.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8fd81e99-e91f-459a-8ccd-89e73fc85941_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25249037","allele":{"id":"https://genegraph.clinicalgenome.org/r/20613d0f-3679-4056-b6eb-b20b17956e54","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.3385G>C (p.Gly1129Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA206587"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ce726685-7a70-4fb6-9db3-5246ac74f207","type":"EvidenceLine","dc:description":"Awarding 0.5 pt because variant was identified by NGS sequencing panel, phenotype is specific, and variant occurs in ATPase domain, a functionally important domain where other pathogenic missense variants cluster.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ce726685-7a70-4fb6-9db3-5246ac74f207_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25249037","allele":{"id":"https://genegraph.clinicalgenome.org/r/bba490cc-da85-4e1f-bf26-e51757db91b6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.3313C>T (p.Arg1105Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA219888"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/973bd7f9-e5e5-4c5a-b12f-f41e4a1c7172","type":"EvidenceLine","dc:description":"Awarding 0.5 pt because variant was identified by NGS sequencing panel, phenotype is specific, and variant occurs in ATPase domain, a functionally important domain where other pathogenic missense variants cluster.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/973bd7f9-e5e5-4c5a-b12f-f41e4a1c7172_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23906836","allele":{"id":"https://genegraph.clinicalgenome.org/r/dec3c02d-df3d-4296-93a5-10042d069911","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.2639C>T (p.Thr880Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372785046"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/53d25e59-3c3f-41d9-8bc2-75456e2a884f","type":"EvidenceLine","dc:description":"Awarding 0.5 pt because variant was identified by NGS sequencing panel, phenotype is specific, and variant occurs in ATPase domain, a functionally important domain where other pathogenic missense variants cluster.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/53d25e59-3c3f-41d9-8bc2-75456e2a884f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23906836","allele":{"id":"https://genegraph.clinicalgenome.org/r/87df1751-29d7-4eea-b817-c5d9f18c1306","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.2554G>A (p.Glu852Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA219874"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/a2abe670-27d7-49c6-81d4-8557582f9c6f","type":"EvidenceLine","dc:description":"Awarding 0.5 pt because only SMARCA2 gene was sequenced, however the phenotype is specific, the variant occurs in important func domain, and mat/pat confirmed by STR analysis.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a2abe670-27d7-49c6-81d4-8557582f9c6f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22822383","allele":{"id":"https://genegraph.clinicalgenome.org/r/ff2f86b8-2db4-447f-8cef-da8df52ac487","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.3563C>A (p.Ala1188Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372788857"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5977a523-41bb-4ff5-a0a1-9897d5b325ee","type":"EvidenceLine","dc:description":"GCEP suggested awarding 1 pt because variant was identified by exome sequencing, phenotype is specific, and variant occurs in ATPase domain, a functionally important domain where other pathogenic missense variants cluster.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5977a523-41bb-4ff5-a0a1-9897d5b325ee_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22366787","allele":{"id":"https://genegraph.clinicalgenome.org/r/a48e8659-d5e9-4511-b2ac-2ab0d798c00c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.3485G>A (p.Arg1162His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA211271"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/14c38007-4064-45de-8163-5b0a072f57f4","type":"EvidenceLine","dc:description":"Awarding 0.5 pt because variant was identified by NGS sequencing panel, phenotype is specific, and variant occurs in ATPase domain, a functionally important domain where other pathogenic missense variants cluster.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/14c38007-4064-45de-8163-5b0a072f57f4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25249037","allele":{"id":"https://genegraph.clinicalgenome.org/r/81f82423-5b8c-4537-9dd3-bf88ab744100","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.3220C>G (p.Gln1074Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372787356"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/7cc6bc95-c725-4898-b002-b072532f7135","type":"EvidenceLine","dc:description":"GCEP suggested awarding 1 pt because variant was identified by exome sequencing, phenotype is specific, and variant occurs in ATPase domain, a functionally important domain where other pathogenic missense variants cluster.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7cc6bc95-c725-4898-b002-b072532f7135_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22366787","allele":{"id":"https://genegraph.clinicalgenome.org/r/7a5fd48b-04ed-42b5-a393-e49550f4403b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.3475C>G (p.Arg1159Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA211267"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/4e5a010b-65b3-4908-8572-0a4a6d31d1a9","type":"EvidenceLine","dc:description":"Awarding 0.5 pt because variant was identified by NGS sequencing panel, phenotype is specific, and variant occurs in ATPase domain, a functionally important domain where other pathogenic missense variants cluster.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4e5a010b-65b3-4908-8572-0a4a6d31d1a9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23906836","allele":{"id":"https://genegraph.clinicalgenome.org/r/6953ec88-1061-4e99-86ec-d27c2641080f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.2564G>A (p.Arg855Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372784870"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/dee414c3-2973-479a-b0ea-c7dc3536c53d","type":"EvidenceLine","dc:description":"Awarding 0.5 pt because only SMARCA2 gene was sequenced, however the phenotype is specific, the variant occurs in important func domain, and mat/pat confirmed by STR analysis.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dee414c3-2973-479a-b0ea-c7dc3536c53d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22822383","allele":{"id":"https://genegraph.clinicalgenome.org/r/d22c2b49-a9d5-476f-b104-b032c149dacd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.3395G>A (p.Gly1132Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA211284"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/bc6625f3-0c2a-44ce-a708-dc1cc3c9c9e3","type":"EvidenceLine","dc:description":"Awarding 0.5 pt because variant was identified by NGS sequencing panel, phenotype is specific, and variant occurs in ATPase domain, a functionally important domain where other pathogenic missense variants cluster.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bc6625f3-0c2a-44ce-a708-dc1cc3c9c9e3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25249037","allele":{"id":"https://genegraph.clinicalgenome.org/r/bc8dca46-4728-4738-b563-8555c3bcb992","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.3377C>G (p.Thr1126Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372788147"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/8bc09e77-7414-49a4-a215-55339abeb3cd","type":"EvidenceLine","dc:description":"GCEP suggested awarding 1 pt because variant was identified by exome sequencing, phenotype is specific, and variant occurs in ATPase domain, a functionally important domain where other pathogenic missense variants cluster.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8bc09e77-7414-49a4-a215-55339abeb3cd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22366787","allele":{"id":"https://genegraph.clinicalgenome.org/r/ea262f00-ca0a-4944-b850-661c9a60bc9c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.3476G>A (p.Arg1159Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA211263"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/fb812df4-91aa-43a2-9121-05c5653afb56","type":"EvidenceLine","dc:description":"GCEP suggested awarding 1 pt because variant was identified by exome sequencing, phenotype is specific, and variant occurs in ATPase domain, a functionally important domain where other pathogenic missense variants cluster.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fb812df4-91aa-43a2-9121-05c5653afb56_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22366787","allele":{"id":"https://genegraph.clinicalgenome.org/r/cd83cd94-b7d2-4e68-9485-249348cdc766","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003070.5(SMARCA2):c.3604G>T (p.Gly1202Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA211261"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":11.5},{"id":"https://genegraph.clinicalgenome.org/r/5cde86bc-f99f-40cf-8c32-eac9f8f8a67d_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5cde86bc-f99f-40cf-8c32-eac9f8f8a67d_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c00705b6-8ba1-4ccb-8731-241ca9b3891e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8226c8af-0981-4f29-80e2-a55241166dcd","type":"FunctionalAlteration","dc:description":"Loss of HO expression and Gal4 activator function","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8871545","rdfs:label":"Effect of SWI2 ATPase motif mutations"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5cde86bc-f99f-40cf-8c32-eac9f8f8a67d_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8423a51e-1218-454c-9208-bf7f2fdc99fc","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0ac71165-6b13-47bc-85b2-8cab29b99708","type":"Finding","dc:description":"The defects in neurogenesis, and the re-targeting of the SWI/SNF complex are plausible explanations for the intellectual disability and the wide range of additional, syndromic clinical features observed in patients with pathogenic SMARCA2 variants.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31375262","rdfs:label":"SMARCA2 variants expressed in human embryonic stem cells","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1.5}],"evidenceStrength":"Definitive","sequence":11361,"specifiedBy":"GeneValidityCriteria7","strengthScore":13,"subject":{"id":"https://genegraph.clinicalgenome.org/r/YrA5nDU48t4","type":"GeneValidityProposition","disease":"obo:MONDO_0011053","gene":"hgnc:11098","modeOfInheritance":"obo:HP_0000006"},"version":"1.6","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_5cde86bc-f99f-40cf-8c32-eac9f8f8a67d-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}